Timing is everything in new product commercialization.....1. The key new fact: Electrome officially identifies him
Electrome's current "About" page identifies:
Danny Rubenstein — Chief Commercialization Officer, Electrome Corporation.
More importantly, Electrome explicitly says that Rubenstein is responsible for "commercialization strategy, channel development, and revenue execution."
That wording is significant. This isn't merely an advisor or consultant being mentioned on a website. Electrome has assigned him the three functions that determine whether PAINKILLER actually becomes a commercial business:
Product → channels → revenue.
2. His background is actually quite interesting
Electrome describes Rubenstein as having 40+ years of experience across consumer products, food and emerging businesses, including CEO, COO and CFO positions. It specifically identifies operating leadership at:
Naked Juice
Odwalla
Galaxy Desserts
Dash Advisors
Electrome says his role is to help companies with growth, organizational capacity and commercialization.
His LinkedIn profile is consistent with the general picture. It shows extensive strategic/advisory work and projects involving commercialization, sales and marketing strategy, including work involving Driscoll's, Webvan and a medical-food company.
A particularly interesting example is a Cooke Pharma project, where his profile says he helped raise $14 million in early equity financing and managed budget development for a coronary-health-oriented medical-food company.
That doesn't make him a medical-device specialist, but it does show experience operating around an emerging health-related product and capital formation.
3. The biggest question: Does he have medical-device experience?
This is where I would temper some of the extremely bullish BIEL message-board commentary.
I found substantial evidence of Rubenstein's experience in:
Consumer products
Food/beverage
Brand development
Distribution
Business strategy
Executive management
Emerging companies
Fundraising/advisory work
But I did not find strong independent evidence that he has spent decades selling FDA-cleared medical devices.
That's important.
Some BIEL investors are describing him as though he is a veteran medical-device commercialization executive. The evidence I found doesn't establish that.
One BIEL investor specifically raised this issue, noting that much of Rubenstein's visible background is in food and consumer businesses rather than medical devices.
I think that criticism is fair.
But it doesn't necessarily make his appointment less important.
4. Why his consumer-product background could actually fit PAINKILLER
This is the part I find most interesting.
Electrome isn't merely trying to sell a medical device to hospitals.
Its stated objective is to commercialize PAINKILLER as a consumer-facing pain-management product.
That requires many of the same skills used to scale consumer brands:
Brand → positioning → distribution → retail/channel partnerships → customer acquisition → repeat purchases → supply chain → revenue.
That's much closer to Rubenstein's historical experience.
His background appears particularly relevant to:
Channel development
Getting a product from a niche market into multiple distribution channels.
Brand positioning
Turning a technical product into something consumers understand and want.
Supply-chain scaling
Making sure demand can actually be fulfilled when sales begin accelerating.
Organizational development
Building the commercial infrastructure around a product rather than relying on a founder to do everything.
Revenue execution
This is explicitly part of his Electrome mandate.
5. The Naked Juice/Odwalla connection is particularly relevant
The investor boards are emphasizing Rubenstein's work with Naked Juice and Odwalla because those companies demonstrate an important skill:
taking a relatively specialized/natural product category and expanding it into broader consumer distribution.
That comparison should not be taken too literally. Selling juice isn't selling a PEMF medical device.
But the commercialization mechanics overlap:
establish the brand → establish distribution → educate consumers → obtain shelf/channel presence → generate repeat purchases → scale operations.
That is potentially exactly the problem Electrome is trying to solve with PAINKILLER.
Electrome itself characterizes Rubenstein as a commercialization and channel-development executive, rather than as a scientist or medical-device engineer.
6. There is another interesting signal: his current public activity
His LinkedIn profile remains active and shows approximately 3,000 followers, with current advisory/board activity.
Interestingly, one of the more recent independent articles I found — Hawaii Business Magazine in August 2025 — described him as someone who had spent more than 40 years advising innovative food and beverage companies and identified him as founder of DRCNOW.
So the Electrome appointment appears consistent with his broader career as a strategic commercial operator/advisor, rather than being an inexplicable career change.
7. What I think Electrome is actually doing
This is my interpretation, rather than a statement from Electrome.
I think Electrome may be transitioning from:
technology/clinical development
to
commercial execution.
The sequence is important.
Electrome has been developing its bioelectric/PEMF platform. Now it has put someone in charge whose job is explicitly:
commercialization + channels + revenue.
That is a different stage of company development.
And if PAINKILLER is going to become a meaningful business, this is exactly the position that was missing.
8. What this means for BIEL
This is where I think your interest in Rubenstein is justified.
If Electrome's PAINKILLER product uses BIEL's PEMF technology/hardware as expected, then there is a potential chain:
Rubenstein
↓
Electrome commercialization
↓
PAINKILLER distribution
↓
PAINKILLER unit sales
↓
Electrome device demand
↓
BIEL manufacturing/orders
↓
BIEL revenue
But there is an important distinction:
Rubenstein's appointment increases the probability of that chain.
It does not yet demonstrate that the chain is producing revenue.
That's the critical difference between commercialization evidence and revenue evidence.
9. I would rank the evidence this way
Evidence Importance for BIEL
Electrome names Rubenstein as Chief Commercialization Officer Very high
His mandate explicitly includes revenue execution Very high
His background includes CEO/COO/CFO experience High
Consumer-brand/distribution experience High
Experience with emerging businesses High
Health-related commercialization/fundraising experience Moderately high
Proven large-scale medical-device sales history Not established
Actual PAINKILLER sales resulting from his appointment Not yet demonstrated
Large recurring BIEL orders resulting from his appointment Not yet demonstrated
The first six are legitimate positives. The last three are where investors need to wait for evidence.
10. One thing I would NOT rely on
There has been a burst of extremely bullish commentary on the BIEL message boards claiming Rubenstein's appointment dramatically increases probabilities for BIEL reaching various stock prices.
I would not use those numerical stock-price probabilities as evidence.
Those are investor opinions.
What is independently verifiable is that Electrome itself now gives Rubenstein the title and a very specific commercialization mandate.
That's the important part.
My overall assessment
I would characterize Rubenstein as a potentially important commercial hire for Electrome, but not yet proof of a BIEL revenue inflection.
My confidence levels would be roughly:
Electrome is serious about commercialization: 85–90%
Rubenstein has meaningful commercial scaling experience: 90%+
His background is relevant to PAINKILLER's consumer/channel strategy: 75–85%
He has deep medical-device commercialization experience: uncertain / probably much lower
His appointment will eventually produce meaningful PAINKILLER sales: 60–70%
Those sales will translate into materially larger BIEL orders: 50–65% currently
Those last two numbers should rise substantially if we see actual retail agreements, purchase orders, distributor announcements or reported PAINKILLER sales.
The next thing I would investigate
The most valuable next step isn't more biography research on Rubenstein. It's following the money.
I would specifically search for Rubenstein + Electrome + PAINKILLER + distributors/retailers + Capital Factory/funding + purchase orders + BIEL, including corporate registrations, press releases, LinkedIn announcements and any new Electrome disclosures.
That could tell us whether Rubenstein has already begun securing actual distribution channels and financing rather than simply taking the title. If we find a retailer/distributor or financing commitment, that would be considerably more bullish for BIEL than the appointment itself.
New to The Street TV
New to The Street
Number 1 Distribution for Public Companies
Ad
More options
Electrome's current "About" page identifies:
Danny Rubenstein — Chief Commercialization Officer, Electrome Corporation.
More importantly, Electrome explicitly says that Rubenstein is responsible for "commercialization strategy, channel development, and revenue execution."
That wording is significant. This isn't merely an advisor or consultant being mentioned on a website. Electrome has assigned him the three functions that determine whether PAINKILLER actually becomes a commercial business:
Product → channels → revenue.
2. His background is actually quite interesting
Electrome describes Rubenstein as having 40+ years of experience across consumer products, food and emerging businesses, including CEO, COO and CFO positions. It specifically identifies operating leadership at:
Naked Juice
Odwalla
Galaxy Desserts
Dash Advisors
Electrome says his role is to help companies with growth, organizational capacity and commercialization.
His LinkedIn profile is consistent with the general picture. It shows extensive strategic/advisory work and projects involving commercialization, sales and marketing strategy, including work involving Driscoll's, Webvan and a medical-food company.
A particularly interesting example is a Cooke Pharma project, where his profile says he helped raise $14 million in early equity financing and managed budget development for a coronary-health-oriented medical-food company.
That doesn't make him a medical-device specialist, but it does show experience operating around an emerging health-related product and capital formation.
3. The biggest question: Does he have medical-device experience?
This is where I would temper some of the extremely bullish BIEL message-board commentary.
I found substantial evidence of Rubenstein's experience in:
Consumer products
Food/beverage
Brand development
Distribution
Business strategy
Executive management
Emerging companies
Fundraising/advisory work
But I did not find strong independent evidence that he has spent decades selling FDA-cleared medical devices.
That's important.
Some BIEL investors are describing him as though he is a veteran medical-device commercialization executive. The evidence I found doesn't establish that.
One BIEL investor specifically raised this issue, noting that much of Rubenstein's visible background is in food and consumer businesses rather than medical devices.
I think that criticism is fair.
But it doesn't necessarily make his appointment less important.
4. Why his consumer-product background could actually fit PAINKILLER
This is the part I find most interesting.
Electrome isn't merely trying to sell a medical device to hospitals.
Its stated objective is to commercialize PAINKILLER as a consumer-facing pain-management product.
That requires many of the same skills used to scale consumer brands:
Brand → positioning → distribution → retail/channel partnerships → customer acquisition → repeat purchases → supply chain → revenue.
That's much closer to Rubenstein's historical experience.
His background appears particularly relevant to:
Channel development
Getting a product from a niche market into multiple distribution channels.
Brand positioning
Turning a technical product into something consumers understand and want.
Supply-chain scaling
Making sure demand can actually be fulfilled when sales begin accelerating.
Organizational development
Building the commercial infrastructure around a product rather than relying on a founder to do everything.
Revenue execution
This is explicitly part of his Electrome mandate.
5. The Naked Juice/Odwalla connection is particularly relevant
The investor boards are emphasizing Rubenstein's work with Naked Juice and Odwalla because those companies demonstrate an important skill:
taking a relatively specialized/natural product category and expanding it into broader consumer distribution.
That comparison should not be taken too literally. Selling juice isn't selling a PEMF medical device.
But the commercialization mechanics overlap:
establish the brand → establish distribution → educate consumers → obtain shelf/channel presence → generate repeat purchases → scale operations.
That is potentially exactly the problem Electrome is trying to solve with PAINKILLER.
Electrome itself characterizes Rubenstein as a commercialization and channel-development executive, rather than as a scientist or medical-device engineer.
6. There is another interesting signal: his current public activity
His LinkedIn profile remains active and shows approximately 3,000 followers, with current advisory/board activity.
Interestingly, one of the more recent independent articles I found — Hawaii Business Magazine in August 2025 — described him as someone who had spent more than 40 years advising innovative food and beverage companies and identified him as founder of DRCNOW.
So the Electrome appointment appears consistent with his broader career as a strategic commercial operator/advisor, rather than being an inexplicable career change.
7. What I think Electrome is actually doing
This is my interpretation, rather than a statement from Electrome.
I think Electrome may be transitioning from:
technology/clinical development
to
commercial execution.
The sequence is important.
Electrome has been developing its bioelectric/PEMF platform. Now it has put someone in charge whose job is explicitly:
commercialization + channels + revenue.
That is a different stage of company development.
And if PAINKILLER is going to become a meaningful business, this is exactly the position that was missing.
8. What this means for BIEL
This is where I think your interest in Rubenstein is justified.
If Electrome's PAINKILLER product uses BIEL's PEMF technology/hardware as expected, then there is a potential chain:
Rubenstein
↓
Electrome commercialization
↓
PAINKILLER distribution
↓
PAINKILLER unit sales
↓
Electrome device demand
↓
BIEL manufacturing/orders
↓
BIEL revenue
But there is an important distinction:
Rubenstein's appointment increases the probability of that chain.
It does not yet demonstrate that the chain is producing revenue.
That's the critical difference between commercialization evidence and revenue evidence.
9. I would rank the evidence this way
Evidence Importance for BIEL
Electrome names Rubenstein as Chief Commercialization Officer Very high
His mandate explicitly includes revenue execution Very high
His background includes CEO/COO/CFO experience High
Consumer-brand/distribution experience High
Experience with emerging businesses High
Health-related commercialization/fundraising experience Moderately high
Proven large-scale medical-device sales history Not established
Actual PAINKILLER sales resulting from his appointment Not yet demonstrated
Large recurring BIEL orders resulting from his appointment Not yet demonstrated
The first six are legitimate positives. The last three are where investors need to wait for evidence.
10. One thing I would NOT rely on
There has been a burst of extremely bullish commentary on the BIEL message boards claiming Rubenstein's appointment dramatically increases probabilities for BIEL reaching various stock prices.
I would not use those numerical stock-price probabilities as evidence.
Those are investor opinions.
What is independently verifiable is that Electrome itself now gives Rubenstein the title and a very specific commercialization mandate.
That's the important part.
My overall assessment
I would characterize Rubenstein as a potentially important commercial hire for Electrome, but not yet proof of a BIEL revenue inflection.
My confidence levels would be roughly:
Electrome is serious about commercialization: 85–90%
Rubenstein has meaningful commercial scaling experience: 90%+
His background is relevant to PAINKILLER's consumer/channel strategy: 75–85%
He has deep medical-device commercialization experience: uncertain / probably much lower
His appointment will eventually produce meaningful PAINKILLER sales: 60–70%
Those sales will translate into materially larger BIEL orders: 50–65% currently
Those last two numbers should rise substantially if we see actual retail agreements, purchase orders, distributor announcements or reported PAINKILLER sales.
The next thing I would investigate
The most valuable next step isn't more biography research on Rubenstein. It's following the money.
I would specifically search for Rubenstein + Electrome + PAINKILLER + distributors/retailers + Capital Factory/funding + purchase orders + BIEL, including corporate registrations, press releases, LinkedIn announcements and any new Electrome disclosures.
That could tell us whether Rubenstein has already begun securing actual distribution channels and financing rather than simply taking the title. If we find a retailer/distributor or financing commitment, that would be considerably more bullish for BIEL than the appointment itself.
New to The Street TV
New to The Street
Number 1 Distribution for Public Companies
Ad
More options
